Quest Diagnostics (DGX) is set to release its third-quarter 2024 results on Oct. 22, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share (EPS) of $2.35 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.73%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.31%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. DGX's Q3 Estimates For the third quarter of ...

Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J., Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system. Financial terms of the transaction were not disclosed. The goal of the transaction is to broaden access to c ...

Quest Diagnostics Inc. (DGX) continues the strong momentum in its expanding portfolio of Advanced Services, which is poised to help it grow in the upcoming quarters. The company strategically deploys AI and automation to improve its operational quality and efficiency, while Invigorate aims to reach its annual target. Its base business volume remains robust, which is highly encouraging. However, the mounting debt burden on its balance sheet and industry headwinds could pose challenges for Quest Diagnostics' ...

SECAUCUS, N.J., Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode ...

Quest Diagnostics (DGX) has been gaining from its existing solid customer relationships, new customer wins, broad health plan access and advanced diagnostics offerings. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving DGX Stock Quest Diagnostics has been experiencing robust volume growth in its core business (excluding COVID testing), banking on the growth of new physician and hospital customers, a more favorable test mix with increased use of advanced diagnostics, continued strength in he ...

Quest Diagnostics (DGX) and Sentara Health Plans announced a multi-year strategic collaboration to expand access to high-quality, affordable and comprehensive laboratory testing for the members of Sentara Health Plans. Per the deal, starting Jan. 1, 2025, DGX will be the exclusive independent national laboratory provider of clinical laboratory and anatomic pathology services for Sentara Health Plans' members, including commercial and government programs. The agreement applies to Sentara Health Plans' member ...

Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va., Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Sentara Health Plans, the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system, today announced a multiyear strategic collaboration designed to expand access to high-quality, affordable and comprehe ...

Quest Diagnostics (DGX) recently purchased Allina Health's select laboratory assets, in line with its strategy to expand through planned acquisitions. The acquisition should help Quest Diagnostics expand its unique and cost-efficient laboratory services in Minneapolis and across Minnesota and western Wisconsin. Financial terms of the deal were not disclosed. Likely Trend of DGX Stock Following the News Following the announcement, shares of the company moved nearly 1.3% north to $156.36 at yesterday's close. ...

SECAUCUS, N.J., Sept. 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from Allina Health. The goal of the transaction is to improve access to high quality and affordable laboratory services for providers and patients in Minnesota and western Wisconsin. Financial details of the transaction were not disclosed. Quest provides a complete portfolio of service ...

文章核心观点 - Zacks Premium是一个可以帮助投资者更自信地投资的研究服务 [1] - Zacks Style Scores是一个根据价值、成长和动量特征对股票进行评分的独特指标体系 [2][3][4] - Zacks Style Scores与Zacks Rank结合使用可以帮助投资者选择更有可能战胜市场的证券 [5][6][7] 行业和公司总结 - Quest Diagnostics是一家总部位于新泽西州Secaucus的诊断信息服务提供商,为医疗机构提供广泛的诊断服务 [8] - Quest Diagnostics目前在Zacks Rank中评为2(买入),VGM评分为B,价值评分为A,显示其具有吸引力的估值指标 [8] - 过去60天内,有9家分析师上调了Quest Diagnostics 2024财年的盈利预测,Zacks一致预测增加了0.11美元至8.89美元,平均盈利惊喜为3.3% [9] - 凭借良好的Zacks Rank和一流的价值及VGM评分,Quest Diagnostics值得投资者关注 [9]